Thymosin Alpha-1: the immune modulator — evidence, dosing, and who it's for

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally produced by the thymus gland. It was first isolated and sequenced by Allan Goldstein in 1977. The synthetic version — marketed as Zadaxin by SciClone Pharmaceuticals — is structurally identical to the endogenous human peptide. Zadaxin is approved in over 70 countries including Italy, China, and multiple Asian and Latin American markets, primarily for hepatitis B, hepatitis C, and immunodeficiency. In the United States, it is available as a prescription compounded peptide through 503A pharmacies under physician supervision.

Thymosin Alpha-1 enhances both branches of the immune system. In the adaptive immune response: it promotes dendritic cell maturation by upregulating MHC class II expression, improving antigen presentation to T-cells. It drives Th1 differentiation (pathogen clearance orientation) over Th2 (allergic/inflammatory orientation), which is the clinically useful shift for infection defence and cancer immune surveillance. In the innate immune response: it increases NK cell cytotoxicity — the front-line response to viral-infected cells and early-stage tumour cells. These mechanisms compound: better dendritic cell function produces better T-cell activation, which co-ordinates NK cell activity.

Hepatitis B: multiple randomised controlled trials show superior seroconversion rates when Tα1 is added to interferon therapy vs interferon alone. Hepatitis C (pre-direct-acting antiviral era): Tα1 as a response enhancer with interferon therapy showed clinically meaningful benefit. Malignant melanoma: adjunct to dacarbazine chemotherapy in Phase II trials showed improved survival signal. COVID-19: Chinese clinical trial (n=76) showed statistically significant reduction in ICU mortality with Tα1 supplementation vs standard of care. Immunodeficiency: case series and open-label trials document T-cell reconstitution in immune-compromised patients.

The thymus gland involutes (progressively shrinks) beginning around age 40. By age 70, thymic output of naïve T-cells is approximately 90% of what it was in young adulthood. This progressive immune dysfunction — immunosenescence — manifests as: increased susceptibility to infections, reduced vaccine efficacy, elevated chronic low-grade inflammation (inflammaging), and increased cancer incidence. Thymosin Alpha-1 partially compensates for declining thymic output by upregulating T-cell differentiation in peripheral lymphoid tissue, effectively extending the functional immune repertoire.

Patients on active GLP-1 therapy are in a sustained caloric deficit. Protein restriction during caloric deficit reduces lymphocyte production capacity — a documented transient immune suppression associated with rapid weight loss. Tα1 at 900mcg twice weekly provides immune support during this metabolically stressed period. This combination has become increasingly common in longevity-focused GLP-1 protocols, particularly for patients over 50 or those with any documented immune function concerns.

Standard protocol: 900mcg subcutaneous twice weekly — typically Monday and Thursday. Duration: 4–12 weeks per cycle. Some longevity protocols use continuous low-dose administration (900mcg once weekly) for maintenance. Monitoring: CBC with differential at baseline and 8 weeks to assess lymphocyte subsets. NK cell activity assay provides the most detailed immune monitoring but is not available at all labs. No dose adjustment is required for kidney or liver function at therapeutic doses. Injection site rotation is recommended for twice-weekly subcutaneous use.

Thymosin Alpha-1 is most appropriate for: patients with more than 4 upper respiratory infections per year, documented post-COVID immune dysfunction (persistent lymphopenia, elevated cytokines), history of cancer with completed treatment seeking immune optimisation, active GLP-1 therapy patients with protein intake concerns, and patients over 50 with documented immunosenescence markers. It is NOT appropriate for: organ transplant recipients on immunosuppressive therapy — Tα1's immune enhancement could contribute to rejection. This is an absolute contraindication.

The naming overlap creates persistent confusion. Thymosin Alpha-1 and Thymosin Beta-4 (TB-500) are unrelated peptides with different sequences, different mechanisms, and different clinical applications. Tα1: immune modulation through T-cell and NK cell pathways. TB-500: actin-binding peptide with tissue repair, anti-inflammatory, and angiogenic properties. They are used for different indications and can be combined in a protocol — Tα1 for immune support, TB-500 for tissue repair and inflammation management. Understanding the distinction is required for appropriate clinical use.

Physician consultation, immune panel baseline, and PCAB-accredited compounding pharmacy access. Prescriptions issued for patients with documented clinical indication.

Frequently Asked Questions